Illumina
Develops sequencing platforms and consumables
Senior Software Quality Engineer
Occasional travel may be required, and the role requires shifts supporting the US region; no night shift is required.
About the job
- At least 5 years of experience in software quality engineering or a related role in a regulated industry.
- Working knowledge of relevant industry standards and regulations, including IEC 62304, ISO 13485, and 21 CFR.
- Strong understanding of software development life cycle processes and software engineering best practices.
- Ability to independently own and execute quality activities for assigned programs with minimal supervision.
- Ability to operate effectively in a fast-paced and dynamic environment.
- Strong collaboration skills with Software Development, Program Management, Product Security, and other cross-functional teams to drive a culture of quality.
- Good interpersonal, verbal, and written communication skills.
- Ability to apply Quality Engineering principles effectively, including structured development processes and risk management.
- Willingness to work in shifts to support the United States region; no night shift is required.
- Occasional travel may be required.
- Serve as a subject matter expert in Software Quality Engineering and act as the primary quality partner for assigned projects.
- Provide end-to-end software quality support across the software development life cycle, with ownership of quality deliverables for assigned areas.
- Collaborate with global cross-functional teams across time zones to ensure alignment and execution.
- Review and approve development deliverables, including Software Development Plans, Verification Plans, Validation Plans, product and software requirements, software architectural and design documents, test protocols, requirements traceability matrices, test reports, and cybersecurity and risk-related documentation.
- Assist teams in determining verification and validation strategies that align with regulatory and quality requirements.
- Participate in and drive software risk management activities throughout the product lifecycle.
- Provide review and approval of software-related orders.
- Participate in design reviews to ensure effective development, transfer, and maintenance of software products across the lifecycle.
- Provide support for software-related issues, including complaints and corrective and preventive actions, through investigation, resolution, and identification of systemic improvements.
- Identify and recommend continuous improvements to the Software Quality Program.
- Assist in developing and delivering training to employees on quality processes and practices.
- Provide support and guidance for developing new technologies, including artificial intelligence and machine learning, cybersecurity, and cloud technologies, as they relate to software systems and tools.
- Support internal and external audits related to product software and software quality processes.
- Contribute to building and scaling Software Quality Engineering capability within the India team, including standardization of processes and best practices.
- Escalate potential risks and issues to management proactively to ensure visibility and timely resolution.
- Support other areas of the Quality System and perform additional tasks as defined by management.
- Experience working in a global delivery model with cross-functional teams across geographies.
- Quality and/or regulatory certifications such as ASQ, AAMI, or RAPS.
- Experience mentoring or guiding junior engineers.
About the company
Illumina provides integrated sequencing platforms and related consumables for analyzing genetic variation and biological function. Its instruments range from high-throughput NovaSeq systems to benchtop MiSeq/iSeq units, all built on sequencing-by-synthesis technology acquired from Solexa. Revenue comes from instrument sales plus a recurring stream of consumables, reagents, library preparation kits, and services. The company differentiates itself with a broad end-to-end ecosystem and strategic acquisitions (Solexa, GRAIL, SomaLogic) that expand capabilities into multiomics and clinical diagnostics.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
San Diego, California
Founded
1998
Get referred to Illumina
See people who can refer or advise you
Simplify's Take
What believers are saying
- Illumina raised 2026 revenue guidance to $4.60 billion-$4.64 billion after Q2 strength.
- S&P 500 inclusion on September 21, 2026 should drive passive-fund buying.
- Clinical volume reached 78% NovaSeq X conversion, supporting recurring consumables growth.
What critics are saying
- FTC and Fifth Circuit GRAIL litigation still threatens forced divestiture and management distraction.
- Research consumables declined in 2026 while clinical demand carried growth, exposing narrow dependence.
- BGI and Thermo Fisher keep pressuring sequencing pricing, risking margin compression by 2027.
What makes Illumina unique
- NovaSeq X drives clinical sequencing workflows, with 95 placements in Q2 2026.
- Illumina pairs sequencing, DRAGEN software, and multiomics tools into one platform.
- The new WGS MRD research solution broadens Illumina beyond core sequencing instruments.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Professional Development Budget
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↓ -2%Illumina will join the S&P 500 index on 21 September, alongside Bloom Energy and Everpure, replacing Molson Coors Beverage, The Trade Desk, and Builders FirstSource. S&P Dow Jones Indices announced the rebalancing on Friday. The San Diego-based genetic sequencing company, valued at $33 billion, has returned 112% over the past 12 months. The inclusion will trigger buying from passive funds tracking the index. Illumina is moving from the S&P MidCap 400, signalling its growth into large-cap status. In the second quarter, the company reported revenue of $1.16 billion, up 9.5% year-over-year, with earnings per share rising approximately 10% to $1.31.
Illumina reported second-quarter revenues of $1.16 billion, marking a 9.4% year-on-year increase that exceeded analyst expectations by 2.5%. The DNA sequencing and microarray technology company delivered strong organic revenue performance and raised its full-year earnings guidance. Chief executive Jacob Thaysen attributed the results to growing momentum in sequencing-intensive applications among clinical customers. The company increased its revenue and earnings guidance for the year based on this performance. Illumina's shares rose 10% following the earnings announcement and currently trade at $225.55. The results came as part of a strong second quarter for the life sciences tools and services sector overall, with the 20 tracked stocks in the group beating revenue estimates by 2.6% on average.
Illumina has entered into a $1 billion credit facility with Bank of America serving as administrative agent. The genomics company announced the agreement after market close on Thursday. The credit facility also includes an underwriting agreement for a note offering, though specific terms were not disclosed in the announcement.
Illumina has filed to issue senior notes maturing in 2029, expecting to raise approximately $750 million. The unsecured notes will rank equally with the company's other unsecured debt and feature a yield near the current US Treasury benchmark. Proceeds will primarily repay an earlier 4.65% note due in September 2026. By extinguishing higher-cost debt, Illumina aims to reduce its interest burden and improve its debt-to-equity ratio. The company expects its weighted average cost of capital to decrease from 5.8% to an estimated 4.9%. The notes include a make-whole redemption clause and a change-of-control provision requiring Illumina to purchase notes at 101% of principal plus interest. Illumina holds Moody's A-3 and S&P A- credit ratings. The refinancing supports ongoing investment in next-generation sequencing platforms, data analytics, and cloud-based services whilst enhancing financial flexibility for strategic acquisitions and R&D funding.
Illumina reported second quarter 2026 revenue of $1.16 billion, up 9.5% from the prior year period. The San Diego-based genomics company posted GAAP diluted earnings per share of $1.35 and non-GAAP diluted earnings per share of $1.31. Chief executive Jacob Thaysen said momentum built through the first half of 2026 as the company's technology enabled clinical customers to expand sequencing-intensive applications. He noted that demand for NovaSeq X remains high. Based on this performance, Illumina raised its full-year 2026 revenue guidance to $4.60-$4.64 billion, up from prior guidance of $4.52-$4.62 billion. The company increased its non-GAAP diluted earnings per share guidance to $5.30-$5.40, versus prior guidance of $5.15-$5.30.